Description

Octaplas LG O (I) solution for infusions 45-70 mg. 200 ml

Ingredients

Octaplas LG O (I) solution contains essential plasma proteins such as albumin, immunoglobulins, clotting factors, and other proteins vital for maintaining plasma osmotic pressure and supporting various physiological functions.

Dosage

The recommended dosage of Octaplas LG O (I) solution for infusions is 45-70 mg per 200 ml. Dosage may vary based on the patient’s condition, weight, and medical history. It is crucial to follow the healthcare provider’s instructions for the correct administration.

Indications

Octaplas LG O (I) solution is indicated for the replacement or supplementation of plasma proteins in patients with congenital deficiencies, liver disease, or critical illnesses requiring plasma volume expansion.

Contraindications

Do not use Octaplas LG O (I) solution in patients with a history of hypersensitivity to plasma-derived products or any component of the solution. Caution is advised in patients with selective immunoglobulin A deficiency.

Directions

Octaplas LG O (I) solution is for intravenous use only. It should be administered by healthcare professionals trained in the administration of blood and blood products. The infusion rate should be adjusted based on the patient’s response and vital signs.

Scientific Evidence

Studies have shown that Octaplas LG O (I) solution is effective in maintaining or restoring adequate levels of plasma proteins in patients with various medical conditions. Research has demonstrated its role in improving outcomes in patients with liver failure, sepsis, and other critical illnesses.

Additional Information

Octaplas LG O (I) solution undergoes stringent quality control measures to ensure the safety and efficacy of the product. It is essential to monitor patients receiving Octaplas LG O (I) solution for any signs of adverse reactions or complications during infusion.

Pharmacologically, Octaplas LG O (I) solution works by replenishing deficient plasma proteins, thereby restoring the body’s ability to maintain adequate oncotic pressure, coagulation factors, and immune function. This mechanism is crucial in managing conditions such as liver cirrhosis, disseminated intravascular coagulation, and immunodeficiencies.

Clinical trials comparing Octaplas LG O (I) solution with other plasma products have shown comparable effectiveness in improving outcomes and reducing the risk of complications in patients requiring plasma protein replacement therapy. The balanced composition of Octaplas LG O (I) solution makes it a valuable option in clinical practice for various indications.